Bristol Myers Squibb (BMY), Microsoft (MSFT) Partner to Enhance Early Lung Cancer Detection Through AI

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best inexpensive stocks to buy now. On January 20, Bristol Myers Squibb announced a partnership with Microsoft (NASDAQ:MSFT) to enhance the early detection of lung cancer. The collaboration centers on integrating Bristol Myers’ oncology expertise with Microsoft’s advanced AI-enabled radiology platform. By using these digital tools, the companies aim to streamline the identification of non-small cell lung cancer, ensuring patients are guided toward optimal care pathways and precision therapies more efficiently.

The initiative will deploy FDA-cleared radiology AI algorithms through the Microsoft Precision Imaging Network. This network is currently used by hospitals across the US to analyze X-ray and CT images. These specific algorithms are designed to assist clinicians in spotting hard-to-detect lung nodules, which is critical for identifying the disease at its earliest, most treatable stages.

A primary objective of this partnership is to bridge the gap in healthcare equity by expanding access to early detection in medically underserved communities. The rollout will specifically target rural hospitals and community clinics across the US, where advanced diagnostic resources may be limited. This unique AI-enabled workflow combines scalable tech with drug delivery expertise to improve patient outcomes.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.